Safety Analysis of Clinical Application of Camrelizumab in 102 Cases
Objective:To explore the safety of camrelizumab in the clinical treatment of patients with malignant tumors,so as to provide reference for clinical rational and safe medication.Methods:A total of 102 tumor patients treated with camrelizumab for injection from 04 Mar 2021 to 30 Oct 2023 in a hospital were retrospectively analyzed and summarized for their general data,medication information,combination medications,immune-related adverse events(irAEs),interventions and outcomes.Results:The patients ranged in age from 32 to 86 years.There were 66 males and 36 females,with a male-to-female ratio of 11:6.Basic diseases were present in 60 patients(58.82%).Combination therapy with anti-angiogenic drugs(such as lenvatinib,anlotinib and apatinib)was given in 52 patients(50.98%).A total of 49 patients experienced irAEs,with the most common event being reactive capillary endothelial proliferation(RCCEP)which was mostly grade G1 or G2.Camrelizumab in combination with anti-angiogenic drugs significantly reduced the incidence of irAEs(P<0.05).The incidence of irAEs with camrelizumab was higher in patients with basic diseases as compared with those without basic diseases(P<0.05).Conclusion:The clinical application of camrelizumab was associated with a high incidence of irAEs,while the severity of them were mild and mostly grade G1～G2,and most of them were resolved with treatment.
万方数据
维普
